CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Pentazocine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00431184
NCT00431184Phase 2Completed
CompareCT.gov

Effects of Pentazocine Versus Lorazepam on Manic Symptoms

Mclean Hospital·interventional·Posted Feb 5, 2007·Updated Mar 6, 2019

In Brief

A Phase 2 clinical trial evaluating Pentazocine and Lorazepam for Bipolar Disorder and 4 related conditions. Completed, enrolled 19 participants across 1 site.

Detailed Summary

Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania, Manic State
CountriesUnited States
CollaboratorsStanley Medical Research Institute

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 5, 2007
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 19.4 years ago

Interventions

Pentazocinedrug

see arms description

Lorazepamdrug

see arms description